8:15–8:40

Abstract 7005^

Confirmatory open-label, single-arm,   multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts)   with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

BiTE   antibody blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r   ALL）的验证性多中心、开放标签的单臂2期研究。

糜坚青(Jian-Qing Mi)

Abstract   7008

Randomized   comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R)   chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the   phase III RESONATE trial.

ibrutinib与ofatumumab在复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE Ⅲ期试验的结果。

Abstract 7026

Results of a prospective, randomized,   open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV)   patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial.

Ruxolitinib（RUX）在羟基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随机、开放标签的Ⅲ期研究结果：RESPONSE试验。

8:40–8:50

专家评述

Discussion Topic: A   comprehensive overview on molecular targeted therapy for leukemia

讨论主题：白血病分子靶向治疗综述

李建勇(Jian-Yong Li)

8:50–8:55

讨论(Q & A)

马  军(Jun Ma)

王健民(Jian-Min Wang)

李建勇(Jian-Yong Li)